HK Stock Market Move | ABBISKO-B(02256) rose more than 5% recently with the latest clinical developments of ibrutinib and piminitinib announced at the ESMO annual meeting.

ABBISKO-B(02256) rose over 5%, as of the time of publication, it rose by 5.77% to HKD 3.3, with a turnover of 3.8013 million Hong Kong dollars. On the news front, Heyo Pharmaceutical recently announced that the company presented the latest clinical data on the safety and efficacy of its independently developed small molecule FGFR4 inhibitor, ipatinib (ABSK011), in Phase 1 clinical trials for advanced liver cancer with FGF19 overexpression at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. It is worth mentioning that this study also won the "Best Poster Award" at the ESMO conference. Data shows that the ipatinib 220mg BID group demonstrated excellent efficacy in FGF19-overexpressing liver cancer patients treated with immune checkpoint inhibitors (ICIs) and multi-targeted small molecule receptor tyrosine kinase inhibitors (mTKIs), with an overall response rate (ORR) of 44.8%, a median duration of response (mDOR) of 7.4 months, and a median progression-free survival (mPFS) of 5.5 months.